Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials
David Wirta1, Amanda M VanDenburgh2, Emily Weng3, Scott M Whitcup4, Sef Kurstjens5, Frederick C Beddingfield III4,61Private Practice, Newport Beach, CA, USA; 2Clinical Development, 3Biostatistics, 4Research and Development, 5Global Drug Development, Allergan, Inc, Irvine, CA, USA; 6Department of Med...
Saved in:
Main Authors: | Wirta D, VanDenburgh A, Weng E, Whitcup S, Kurstjens S, Beddingfield F 3rd |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2011
|
Subjects: | |
Online Access: | https://doaj.org/article/426dcbdab9104b9089a9f1ff9b7ba3f1 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes
by: Shafiee A, et al.
Published: (2013) -
Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits
by: Abayomi B Ogundele, et al.
Published: (2010) -
Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events
by: Tsumura T, et al.
Published: (2012) -
Bimatoprost ophthalmic solution 0.03% lowered intraocularpressure of normal-tension glaucoma with minimal adverse events [Corrigendum]
by: Tsumura T, et al.
Published: (2013) -
Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]
by: Tsumura T, et al.
Published: (2013)